a close up of a pen


Elanco Animal Health Incorporated announces sale and development agreement for four technologies with EVAH Corp.

On May 25, 2021, Elanco Animal Health Incorporated (NYSE: ELAN) (Elanco or "the Company") announced the signing of four contracts with EVAH Corp. (EVAH or "the Company) to develop technologies in animal health. Elanco is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. EVAH is a biotechnology company specializing in the development of biologicals to help prevent bacterial diseases in food animals and microbiome solutions for growth performance.

The four contracts between EVAH and Elanco relate to four products in development (two feed additives and two vaccines) targeting three species: salmon, swine and poultry. Terms of the deal remain confidential.

BLG represented Elanco with a team led by Jason Howg (Intellectual Property) that included Jordan Furfaro and Neil Hazan and Benjamin Gross  (Corporate/Commercial) and paraprofessional Nathalie Olivier.